{"id":"seasonal-inactivated-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"10–40","effect":"Injection site soreness or erythema"},{"rate":"5–15","effect":"Myalgia"},{"rate":"5–15","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"1–5","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Seasonal inactivated influenza vaccine contains inactivated (killed) influenza virus particles or viral antigens that trigger both humoral (antibody) and cell-mediated immune responses. Upon vaccination, the immune system recognizes these antigens and develops protective immunity, enabling faster and more effective recognition and neutralization of circulating influenza viruses if exposure occurs.","oneSentence":"The vaccine stimulates the immune system to produce antibodies and cellular immunity against seasonal influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:03.104Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza in adults and children ≥6 months of age"}]},"trialDetails":[{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06599658","phase":"PHASE2","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-11-20","conditions":"COVID 19, Influenza, Rheumatoid Arthritis (RA)","enrollment":660},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT03501576","phase":"","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2018-04-06","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":200},{"nctId":"NCT05108818","phase":"PHASE4","title":"Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-10-07","conditions":"Influenza, Human","enrollment":700},{"nctId":"NCT00782431","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-11","conditions":"Influenza","enrollment":3208},{"nctId":"NCT00800605","phase":"PHASE3","title":"Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-12","conditions":"Influenza","enrollment":7250},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT03945825","phase":"PHASE1","title":"Flublok or Fluzone With Advax-CpG55.2 or AF03","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-10","conditions":"Influenza, Influenza Immunisation","enrollment":241},{"nctId":"NCT06125691","phase":"PHASE1","title":"Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Influenza, Human","enrollment":139},{"nctId":"NCT06664151","phase":"EARLY_PHASE1","title":"A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-11-26","conditions":"Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer","enrollment":25},{"nctId":"NCT06355232","phase":"PHASE1","title":"Covid-19 and Influenza Oral Vaccine Study","status":"RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2024-05-01","conditions":"covid19 Infection, Influenza, Human","enrollment":100},{"nctId":"NCT04101838","phase":"PHASE4","title":"B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-04-01","conditions":"Influenza","enrollment":50},{"nctId":"NCT01773928","phase":"PHASE3","title":"Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2013-01","conditions":"Influenza","enrollment":1928},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT03315975","phase":"PHASE4","title":"Flu Vaccine Responses in the Setting of Melanoma Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-10-20","conditions":"Viral Vaccines","enrollment":40},{"nctId":"NCT03346772","phase":"PHASE4","title":"Study of Immune Responses to Influenza Vaccination","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-10-20","conditions":"Influenza Vaccination","enrollment":75},{"nctId":"NCT05663463","phase":"NA","title":"Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-09-11","conditions":"Solid Organ Transplant","enrollment":74},{"nctId":"NCT05827978","phase":"PHASE3","title":"Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-17","conditions":"Seasonal Influenza","enrollment":8411},{"nctId":"NCT04896086","phase":"PHASE1","title":"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-24","conditions":"Influenza, Seasonal Influenza","enrollment":63},{"nctId":"NCT05028634","phase":"PHASE3","title":"Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-11-11","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":63},{"nctId":"NCT05566639","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-14","conditions":"Seasonal Influenza","enrollment":22502},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT03755427","phase":"PHASE2","title":"A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-10","conditions":"H7N9 Influenza","enrollment":560},{"nctId":"NCT05895955","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mahidol University","startDate":"2023-11-04","conditions":"Influenza","enrollment":290},{"nctId":"NCT05415462","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-06","conditions":"Seasonal Influenza","enrollment":6102},{"nctId":"NCT03160118","phase":"PHASE4","title":"Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2017-03-27","conditions":"Prevention of Influenza","enrollment":20},{"nctId":"NCT05310084","phase":"PHASE3","title":"Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-04-20","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1134},{"nctId":"NCT03615482","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-14","conditions":"Pneumococcal Infections","enrollment":1200},{"nctId":"NCT05970887","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines","status":"COMPLETED","sponsor":"Catholic Kwandong University","startDate":"2022-10-12","conditions":"Immune Response, Safety","enrollment":154},{"nctId":"NCT05981846","phase":"PHASE2","title":"A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-09-04","conditions":"SARS CoV 2 Infection, Influenza, Human","enrollment":279},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":"Influenza","enrollment":632},{"nctId":"NCT05616546","phase":"PHASE4","title":"Bone Marrow and Peripheral Blood Immune Responses Study","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-10-16","conditions":"Influenza","enrollment":90},{"nctId":"NCT02957890","phase":"PHASE4","title":"Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2016-11-18","conditions":"Influenza, Human","enrollment":400},{"nctId":"NCT05301322","phase":"PHASE3","title":"Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-13","conditions":"Respiratory Syncytial Virus","enrollment":1471},{"nctId":"NCT02385123","phase":"PHASE4","title":"Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-04-01","conditions":"Influenza, Influenza Immunisation","enrollment":60},{"nctId":"NCT00566345","phase":"PHASE3","title":"Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-11","conditions":"Influenza","enrollment":3670},{"nctId":"NCT05996549","phase":"PHASE4","title":"Cost-effectiveness of the Influenza Vaccination","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-09-29","conditions":"Influenza Vaccine, Cost-Effectiveness, Vaccination","enrollment":2567},{"nctId":"NCT04695717","phase":"PHASE3","title":"This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-09-05","conditions":"Influenza","enrollment":864},{"nctId":"NCT05062759","phase":"PHASE3","title":"Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-08-23","conditions":"Moderate to Severe Asthma","enrollment":70},{"nctId":"NCT01344057","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Seasonal Influenza","enrollment":63},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT03930017","phase":"","title":"Pregnancy, Arsenic and Immune Response","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-10-14","conditions":"Arsenic--Toxicology, Immunologic Disorders Complicating Pregnancy, Vaccine Response Impaired","enrollment":784},{"nctId":"NCT01676402","phase":"PHASE1","title":"Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-08","conditions":"Influenza","enrollment":316},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT04133584","phase":"PHASE4","title":"The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2019-09-16","conditions":"Seasonal Influenza, Hand, Foot and Mouth Disease","enrollment":1134},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT04526574","phase":"PHASE3","title":"Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-09-01","conditions":"Pneumococcal Disease","enrollment":1796},{"nctId":"NCT03765437","phase":"PHASE3","title":"Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-01-15","conditions":"Influenza","enrollment":230},{"nctId":"NCT03673345","phase":"PHASE4","title":"Development of Childhood Anti-Influenza Immunity","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-09-25","conditions":"Influenza, Influenza Immunisation","enrollment":125},{"nctId":"NCT03553940","phase":"PHASE1","title":"H3N2 M2SR in Pediatric Population","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-08-15","conditions":"Influenza, Influenza Immunisation","enrollment":43},{"nctId":"NCT02559505","phase":"NA","title":"Influenza Immunity in Children","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2015-10","conditions":"Influenza","enrollment":134},{"nctId":"NCT03328325","phase":"PHASE4","title":"Age and Response to Flu Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-12-14","conditions":"Influenza, Influenza Immunisation","enrollment":152},{"nctId":"NCT03275389","phase":"PHASE1","title":"A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-08","conditions":"Influenza, Human","enrollment":470},{"nctId":"NCT00987350","phase":"PHASE4","title":"Safety Study of Seasonal Influenza Vaccine by Jet Injection","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-01","conditions":"Healthy Adults","enrollment":60},{"nctId":"NCT02451332","phase":"NA","title":"Prenatal Inflammation and Perinatal Outcomes","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2015-10","conditions":"Pregnancy","enrollment":46},{"nctId":"NCT01157702","phase":"PHASE3","title":"Yearly Strain Variation Study, 2010/2011","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2010-07","conditions":"Influenza, Seasonal Influenza","enrollment":110},{"nctId":"NCT01422200","phase":"PHASE4","title":"Flu Vaccine Study in Neuromuscular Patients 2011","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2011-08","conditions":"Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, Congenital Muscular Dystrophy","enrollment":22},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT03318315","phase":"PHASE2","title":"Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-02-20","conditions":"Avian Influenza, Influenza, Influenza Immunisation","enrollment":149},{"nctId":"NCT02263131","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2013-10","conditions":"Healthy","enrollment":416},{"nctId":"NCT03058692","phase":"PHASE2","title":"Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-04-09","conditions":"Influenza, Influenza Immunisation","enrollment":120},{"nctId":"NCT02148211","phase":"","title":"Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-01","conditions":"Influenza","enrollment":507},{"nctId":"NCT03390166","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-24","conditions":"Influenza","enrollment":945},{"nctId":"NCT02894840","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-11","conditions":"Influenza","enrollment":340},{"nctId":"NCT03460743","phase":"PHASE3","title":"Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.","status":"COMPLETED","sponsor":"Laboratorios Liomont","startDate":"2018-03-22","conditions":"Influenza, Human","enrollment":1556},{"nctId":"NCT04101435","phase":"PHASE3","title":"Immunogenicity and Safety Evaluation of QIS in Healthy Subjects","status":"COMPLETED","sponsor":"Adimmune Corporation","startDate":"2016-12-28","conditions":"Influenza","enrollment":174},{"nctId":"NCT02500680","phase":"PHASE1","title":"The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)","status":"UNKNOWN","sponsor":"Nova Immunotherapeutics Limited","startDate":"2015-07","conditions":"Influenza, Human","enrollment":102},{"nctId":"NCT03095599","phase":"PHASE2, PHASE3","title":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2017-03-20","conditions":"Influenza, Human","enrollment":889},{"nctId":"NCT02438423","phase":"PHASE1","title":"Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle","status":"COMPLETED","sponsor":"Mark Prausnitz","startDate":"2015-06","conditions":"Influenza","enrollment":100},{"nctId":"NCT02935192","phase":"PHASE3","title":"Phase 3 Trial of Serbian Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Institute of Virology, Vaccines and Sera, Torlak","startDate":"2016-11-28","conditions":"Influenza","enrollment":480},{"nctId":"NCT02598089","phase":"PHASE1","title":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2015-11","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT03392207","phase":"","title":"Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2018)","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2018-04-23","conditions":"Influenza, Human, Orthomyxoviridae Infections, RNA Virus Infections","enrollment":403},{"nctId":"NCT02585700","phase":"PHASE1","title":"A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine","status":"COMPLETED","sponsor":"Institute of Virology, Vaccines and Sera, Torlak","startDate":"2015-11","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT01978262","phase":"PHASE4","title":"Immune and Hormone Response to Influenza Vaccine","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2013-10","conditions":"Healthy","enrollment":103},{"nctId":"NCT03784885","phase":"PHASE2","title":"A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult","status":"COMPLETED","sponsor":"Advagene Biopharma Co. Ltd.","startDate":"2017-09-01","conditions":"Influenza Infection","enrollment":345},{"nctId":"NCT01609998","phase":"PHASE1","title":"Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-06","conditions":"Influenza","enrollment":75},{"nctId":"NCT03300362","phase":"PHASE2","title":"Improved Novel VaccIne CombinaTion InflUenza Study","status":"TERMINATED","sponsor":"Barinthus Biotherapeutics","startDate":"2017-10-13","conditions":"Influenza","enrollment":862},{"nctId":"NCT01924169","phase":"PHASE2","title":"Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-11-24","conditions":"Hematologic Disorder","enrollment":3},{"nctId":"NCT01811823","phase":"PHASE4","title":"Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2014-03-31","conditions":"Influenza, HIV, Tuberculosis","enrollment":301},{"nctId":"NCT00985673","phase":"PHASE2","title":"Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-01","conditions":"Influenza","enrollment":611},{"nctId":"NCT03572491","phase":"PHASE3","title":"Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2017-09-18","conditions":"Human Influenza","enrollment":2000},{"nctId":"NCT03016143","phase":"PHASE2","title":"Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2016-10","conditions":"Influenza","enrollment":300},{"nctId":"NCT02133781","phase":"PHASE4","title":"B-cell Immunity to Influenza (SLVP017)- Year 1, 2009","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-07","conditions":"Influenza","enrollment":51},{"nctId":"NCT03020537","phase":"PHASE4","title":"B-cell Immunity to Influenza (SLVP017)- Year 5, 2013","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-10","conditions":"Influenza","enrollment":8},{"nctId":"NCT02545543","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2015-09","conditions":"Influenza, Human","enrollment":2278},{"nctId":"NCT02141581","phase":"PHASE4","title":"Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-08","conditions":"Influenza","enrollment":86},{"nctId":"NCT01685372","phase":"PHASE2","title":"Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-09","conditions":"Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV)","enrollment":16},{"nctId":"NCT03057483","phase":"","title":"Active Surveillance for Adverse Events Following Immunization With the Influenza Vaccine Produced at Butantan Institute","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2017-04-06","conditions":"Influenza Vaccines","enrollment":533},{"nctId":"NCT02655874","phase":"PHASE4","title":"Tropical Influenza Control Strategies for the Elderly","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2016-05","conditions":"Influenza, Human","enrollment":200},{"nctId":"NCT03028987","phase":"PHASE4","title":"Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)","status":"TERMINATED","sponsor":"Stanford University","startDate":"2014-11-19","conditions":"Influenza","enrollment":10},{"nctId":"NCT02362919","phase":"","title":"Influenza Vaccination Among the Elderly Individuals","status":"COMPLETED","sponsor":"Helmholtz Centre for Infection Research","startDate":"2015-02","conditions":"Influenza","enrollment":200},{"nctId":"NCT03022396","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Influenza","enrollment":82},{"nctId":"NCT03022422","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-09","conditions":"Influenza","enrollment":63},{"nctId":"NCT01827462","phase":"PHASE4","title":"Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2007-10","conditions":"Influenza","enrollment":136},{"nctId":"NCT00858611","phase":"PHASE1","title":"VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-03-03","conditions":"Influenza, Human","enrollment":51},{"nctId":"NCT00995982","phase":"PHASE1","title":"VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-10-08","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT01831934","phase":"PHASE4","title":"Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"MELAS Syndrome","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SIIV","FluZone"],"phase":"marketed","status":"active","brandName":"Seasonal Inactivated Influenza Vaccine","genericName":"Seasonal Inactivated Influenza Vaccine","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"The vaccine stimulates the immune system to produce antibodies and cellular immunity against seasonal influenza virus strains. Used for Prevention of seasonal influenza in adults and children ≥6 months of age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}